FDA Approves Expanded Indication for Merck?s KEYTRUDA? (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

- in combination with platinum- and fluoropyrimidine-based chemotherapy, or
- as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS =10) as determined by an FDA-approved test.